SLY is an oxaborole-functionalized fluorescent probe that targets sialyl Lewis antigens (sLeᵃ/sLeˣ) by binding terminal sialic acid on cancer cell surfaces, enabling selective fluorescence labeling. After binding, SLY is internalized via caveolae-mediated endocytosis and accumulates in mitochondria; this selectivity is supported by decreased signals upon sialidase treatment and inhibited uptake with Filipin. SLY provides high-contrast imaging in cancer cells (e.g., HepG2 and HT29) and tumor tissues versus normal counterparts, highlighting its potential for high-fidelity cancer tissue imaging and fluorescence-guided surgical applications.
■ Image
(d)Fluorescence imaging of celllines using SLY. COS7, Hep3B, HepG2, and HT29 cells were incubated with SLY(50nM) for 1h prior to imaging.
(b) Tissue imaging after incubation with SLY. Liver tissues, obtained from both normal and DEN-induced liver cancer mice, were incubated with SLY (5.0 μM) for 1 h.
■ Known Property Sialyl Lewis cancer cells probe ■ Application Live cell Imaging / Tissue Imaging In vivo / Ex vivo Imaging ■ Cell selectivity mechanism COLD (sialic acid on sLeᵃ/sLeˣ)
■ Reference
1.
Oxaborole-Functionalized Sialylated Glycan Probe for High-Fidelity Fluorescence Imaging of Cancer Tissue. Ko, K.; Gao, M.; Sarkar, S.; Kwon, H.-Y.; Chang, Y.T.* J. Am. Chem. Soc. 2025, 147, 19718–19726.
■ ORDER
International
USD 350 + VAT (10%) + Fedex delivery charge
In Korea
KRW 450,000 + VAT (10%)
100 nmol (dried form: equivalent to 1 mM / 100 µL)